ฯใฝถสำฦต

Boyu Hu
( out of 101 reviews )

Boyu Hu, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-213-3718

  • Dr. Boyu Hu is an Associate Professor of Medicine and the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/ฯใฝถสำฦต of Utah. He specializes in treating and performing research in patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL. He is primarily a clinical researcher and has been the principal investigator on over 20 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. Furthermore, he is an active participant within the Southwest Oncology Group and the National Clinical Trials Network. He is currently the co-chair and national principal investigator for AHOD2131, which is a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 101 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 11, 2024
    HUNTSMAN CANCER CENTER

    I would highly recommend Dr. Hu. His knowledge and experience makes this very stressful life event much more palatable.

    October 11, 2024
    HUNTSMAN CANCER CENTER

    Dr. Hu is an exceptional dr. He knows his field. He communicates very well with his patients.

    October 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Hu listens and helps you understand what happening to you body. He is a great Dr.

    September 05, 2024
    HUNTSMAN CANCER CENTER

    I couldn't have asked for a better doctor than Dr. Hu! He fosters meaningful relationships with his patients and helps them to live their best life

    July 21, 2024
    HUNTSMAN CANCER CENTER

    Thank you for your guidance and support in battling this illness for the last 2 years.

    June 24, 2024
    HUNTSMAN CANCER CENTER

    Very Patient with our questions and explained things so we could understand best as possible.

    June 09, 2024
    HUNTSMAN CANCER CENTER

    Great Doctor, will take the time to listen and answer question.

    June 08, 2024
    HUNTSMAN CANCER CENTER

    He possessed excellent interpersonal skills and his explanations are easily understood.

    June 01, 2024
    HUNTSMAN CANCER CENTER

    Very concerned about my health and takes the time to answer questions from both me and my wife.

    See More Patient Comments

  • Dr. Boyu Hu is an Associate Professor of Medicine and the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/ฯใฝถสำฦต of Utah. He specializes in treating and performing research in patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL. He is primarily a clinical researcher and has been the principal investigator on over 20 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. Furthermore, he is an active participant within the Southwest Oncology Group and the National Clinical Trials Network. He is currently the co-chair and national principal investigator for AHOD2131, which is a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - ฯใฝถสำฦต of Texas MD Anderson Cancer Center Fellow
    Residency Internal Medicine - Hospital of the ฯใฝถสำฦต of Pennsylvania Resident
    Internship Internal Medicine - Hospital of the ฯใฝถสำฦต of Pennsylvania Intern
    Professional Medical Medicine - Case Western Reserve ฯใฝถสำฦต School of Medicine M.D.
    Undergraduate Duke ฯใฝถสำฦต B.S.

    Selected Publications

    Journal Article

    1. Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM (2024). Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. ()
    2. Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC (2024). Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica. ()
    3. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW (2024). Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med, 391(15), 1379-1389. ()
    4. Azim A, Hu B, Gilligan S, Sarwal A, Hartsell S, Pandya V, Raphael KL (2023). How I Evaluate a High Anion Gap Metabolic Acidosis. Clin J Am Soc Nephrol, 19(4), 525-527. ()
    5. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv, 7(21), 6630-6638. ()
    6. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. ()
    7. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H (2023). NCCN Guidelinesยฎ Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw, 21(11), 1118-1131. ()
    8. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. ()
    9. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Hodgson D, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum K, Perry AM, Kovach A, Constine LS, Shields LK, Prica A, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW (2023). 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol, 41 Suppl 2, 33-35. ()
    10. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol, 98(7), E172-E174.
    11. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & Lymphoma, 64(2), 356-363. ()
    12. Parson MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Medicine, 12(3), 2624-2636.
    13. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40โ€‰years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. ()
    14. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2021). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clin Cancer Res, 28(15), 3242-3247. ()
    15. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. ()
    16. Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanovich M, Lazarski C, Shibli A, Maglo P, Hog F, Schore R, Glenn M, Hu B, Hanley P, Ambinder R, Bollard CM (2021). Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma. Blood Adv, 6, 473-485. ()
    17. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. J Transl Genet Genom, 5, 189-199. ()
    18. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG (2019). Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol, 185(5), 852-864.
    19. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Bose P, Estov Z, Keating M, Wierda WG (2019). Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol, 187(3), 307-318.
    20. Hu B, Takahashi K, et al (2018). Clinical Implications of Cancer Gene Mutations in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide. Blood, 131(16), 1820-32.
    21. Hu Z, Hu B, Collins JF (2007). Prediction of synergistic transcription factors by function conservation. Genome Biol, 8(12), R257. ()

    Review

    1. Hu B, Oki Y (2018). Novel Immunotherapy Options for Extranodal NK/T-cell Lymphoma. [Review]. Front Oncol, 8(139).

    Case Report

    1. Gociman S, Baron K, Hu B, Zussman J, Madigan LM (2022). Blistering Lesions Associated With Loncastuximab Tesirine. JAMA Dermatol, 158(7), 831-832. ()
    2. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal G (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw, 20(6), 1-4. ()

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. ()
    2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. ()

  • Clinical Trials